LIVE MARKETS-Targeted cancer therapies market set to reach $31 billion by 2030

NEW YORK, Sept 2 (Rtrs) - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com.

TARGETED CANCER THERAPIES MARKET SET TO REACH $31 BILLION BY 2030

The market for antibody-drug conjugates (ADCs), a lucrative class of targeted cancer therapies often described as "guided missiles", is projected to reach $31 billion by 2030, based on currently approved drugs, according to analysts at brokerage TD Cowen.

ADCs are designed to selectively kill tumor cells while sparing healthy ones, offering a more targeted approach than traditional chemotherapy, which can harm both.

The innovative class of cancer treatments combine targeted therapy and chemotherapy to deliver directly to diseased cells, acting as a "silver bullet" to limit systemic exposure to toxic drugs, the analysts noted.

The field has made notable progress in recent years, with 13 approved therapies across different types of cancer amounting to a $11.5 billion market in 2024. However, the first generation therapies face certain drawbacks of toxicity and resistance.

The focus is now shifting to questions regarding selection of target, drug payload, and conjugation technology, and development strategy.

The market potential could exceed current projections as new ADCs expand into more cancer types, and move into earlier stages of treatment.

On the other hand, bispecific antibody drug conjugates (bsADC) are an emerging therapeutic approach that presents advantages over traditional ADCs, according to GlobalData.

They use bispecific antibodies that bind to two different targets, making treatments more precise and reducing side effects.

There are four therapies currently in late-stage development for East Asian markets. Systimmune and Bristol Myers Squibb’s BMY.N izalontamab brengitecan, Shanghai JMT-Bio Technology’s JSKN-003, and Chia Tai Tianqing Pharmaceutical Group’s TQB-2102 are focused on China, whereas Amgen’s AMGN.O maridebart cafraglitide targets the Japanese market.

"This regional concentration aligns with the dominance of Chinese companies in ADC development and suggests that the first bsADC approval may occur in Asia, rather than in the US or EU," said Jasper Morley, Pharma Analyst at GlobalData.

(Sriparna Roy)

FOR TUESDAY'S OTHER LIVE MARKETS POSTS:

DE MINIMIS EXEMPTION ENDING, MAXIMUM CHAOS BEGINNING? CLICK HERE

WALL STREET STARTS SEPTEMBER IN THE RED, TARIFFS IN FOCUS CLICK HERE

APPLE'S AUGUST SURGE SETS THE STAGE FOR A HIGH-STAKES SEPTEMBER CLICK HERE

HOW WIDE IS TOO WIDE FOR OAT-BUND SPREAD? CLICK HERE

UBS OPTIMISTIC ON SOARING EUROPEAN BANKS, EVEN AS NEGATIVE NEWS TAKES A BITE CLICK HERE

NESTLE, REAL ESTATE SHARES DRAG STOXX DOWN AS BONDS TUMBLE CLICK HERE

NESTLE IN STICKY SITUATION, MUCH LIKE EURO ZONE INFLATION CLICK HERE

EUROPEAN FUTURES LITTLE CHANGED AHEAD OF EURO ZONE INFLATION CLICK HERE